Search Results

Fresh Tracks Therapeutics, Inc. announced it has entered into an amendment to its Asset Purchase Agreement with Botanix Pharmaceuticals Limited and its subsidiary, Botanix SB Inc., to sell its rights to future event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc. for $8.25 million.

Brickell Biotech, Inc. announced that it has signed and closed a definitive asset purchase agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, whereby Botanix has acquired the Company’s rights to sofpironium bromide, a retrometabolically-designed new chemical entity that belongs to a class of medications called anticholinergics.

New data has shown that a new drug candidate from Botanix’s cannabidiol antimicrobial platform has potent activity against hypervirulent strains of the bacteria Clostridium difficile

Mr Vince Ippolito, a US-based dermatology industry leader with over 30 years of pharmaceuticals experience, appointed as Executive Chairman of Botanix Pharmaceuticals

Appointment of Mr Vince Ippolito, a US-based dermatology industry leader with over 30 years of pharmaceuticals experience as President of Botanix

Botanix will be presenting at the 27th EADV Congress in Paris, France

Botanix has treated the first patient in its BTX 1308 psoriasis Phase 1b patient study

Botanix receives R&D Tax Incentive refund of A$4.6m

Botanix has received Human Research Ethics Committee approval to commence the planned BTX 1308 psoriasis Phase 1b patient study

Botanix Pharmaceuticals Limited is pleased to announce the receipt of firm commitments in respect of a A$40m placement led by specialist US-based biotech investment funds and leading US institutional investors, as well as the appointment of two new experienced dermatology executives.